Author

C. F. O'Brien

Observed names: C F O'Brien, Chris F. O'Brien, Chris O’Brien

Institution: Neurocrine Biosciences (United States)

Observed institutions: Mayo Clinic, University of Miami, Oregon Health & Science University, Vanderbilt University, University of South Florida, CHI Health Creighton University Medical Center - Bergan Mercy, University of Rochester Medicine, Colorado Neurological Institute, Elan Pharmaceuticals, Inc. (Ireland), University of Rochester, Neurocrine Biosciences (United States)

OpenAlex ID: A5111524829

Botulinum toxin type A in the treatment of upper extremity spasticity

1996 · D. M. Simpson, D. N. Alexander, et al. · Neurology · 418

Ropinirole for the treatment of early Parkinson's disease

1997 · C. H. Adler, K. D. Sethi, et al. · Neurology · 284

The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain

2010 · Carla R. Jungquist, Chris O’Brien, et al. · Sleep Medicine · 257

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1991 · J. T. Greenamyre, C. F. O'Brien · Archives of Neurology · 226

Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

2013 · Michael P. Diamond, Bruce Carr, et al. · Reproductive Sciences · 122

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

1997 · Peter G. Como, Allen J. Rubin, et al. · Movement Disorders · 73

Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients.

1998 · P A Cullis, C F O'Brien, et al. · PubMed · 23

Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease.

1995 · A A Ansari, A Mayne, et al. · PubMed · 16

The clinical profile of elan pharmaceuticals' botulinum toxin type B

2001 · C. F. O'Brien · European Journal of Neurology · 4

Chemodenervation with botulinum toxin for spasticity and dystonia. The effects on gait.

2001 · C F O'Brien · PubMed · 3

Works count: 10

Citation count: 1,426

H-index: 8

I10-index: 8